Skip to content

Main Navigation

Clinical Study

Improving Health of Children with MS

Kesimpta® and Mayzent® are potential medications for children with Multiple Sclerosis (MS). Scientists and doctors need to learn the safety and effectiveness of these medications to improve the health of children with MS.


For more information contact:

Trieste Francis

IRB#: IRB_00145728 | PI: M. Mateo Paz Soldan | Department: NEUROLOGY | Approval Date: 2022-04-13 06:00:00
Study Categories: Brain Health Studies | Specialties: Neurology

Who can participate?

 Gender: All

 Age: Over 7 years old

 Volunteers: Volunteers with special conditions

 Location: In Person

Inclusion Criteria:

  • Between 10-18 years old
  • A formal Pediatric MS diagnosis
  • At least one MS relapse/attack during the previous year OR two MS relapses total in the previous two years

Will I be paid for my time?


Last Updated: 4/5/21